148 related articles for article (PubMed ID: 19668713)
1. Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany.
Feucht N; Matthias H; Lohmann CP; Maier M
Clin Ophthalmol; 2008 Jun; 2(2):253-9. PubMed ID: 19668713
[TBL] [Abstract][Full Text] [Related]
2. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
Maier M; Feucht N; Huebner M; Lohmann C
Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with pegaptanib sodium.
Rosina C; Bottoni F; Staurenghi G
Clin Ophthalmol; 2008 Sep; 2(3):485-8. PubMed ID: 19668746
[TBL] [Abstract][Full Text] [Related]
4. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
Quiram PA; Hassan TS; Williams GA
Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
[TBL] [Abstract][Full Text] [Related]
5. Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK.
Sivaprasad S; Acharya N; Hykin P
Clin Ophthalmol; 2008 Jun; 2(2):347-54. PubMed ID: 19668726
[TBL] [Abstract][Full Text] [Related]
6. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V
Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
8. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
Williams AJ; Fekrat S
Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868
[TBL] [Abstract][Full Text] [Related]
9. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
10. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy.
Arias L
Clin Ophthalmol; 2010 Apr; 4():369-74. PubMed ID: 20463807
[TBL] [Abstract][Full Text] [Related]
11. RPE tears after pegaptanib treatment in age-related macular degeneration.
Chang LK; Flaxel CJ; Lauer AK; Sarraf D
Retina; 2007 Sep; 27(7):857-63. PubMed ID: 17891009
[TBL] [Abstract][Full Text] [Related]
12. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
13. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study).
Ishibashi T;
Jpn J Ophthalmol; 2013 Sep; 57(5):417-23. PubMed ID: 23860781
[TBL] [Abstract][Full Text] [Related]
15. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
Atmani K; Coscas F; Coscas G; Soubrane G
Eye (Lond); 2009 May; 23(5):1150-4. PubMed ID: 18636083
[TBL] [Abstract][Full Text] [Related]
16. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.
Lazic R; Gabric N
Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):68-73. PubMed ID: 17111146
[TBL] [Abstract][Full Text] [Related]
17. Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration.
Sivaprasad S
Clin Ophthalmol; 2008 Jun; 2(2):339-46. PubMed ID: 19668725
[TBL] [Abstract][Full Text] [Related]
18. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience.
Sivaprasad S; Hykin P; Saeed A; Beatty S; Grisanti S; Staurenghi G; Olea JL; Campos A; Barbosa A; Rito L; Silva R; Faria R; Eldem B; Kadayifçilar S; Kolar P; Feucht N; Maestroni L
Eye (Lond); 2010 May; 24(5):793-8. PubMed ID: 19786957
[TBL] [Abstract][Full Text] [Related]
20. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Schiller DS
Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
